Glaukos Analysts Boost Their Forecasts Following Better-Than-Expected Q3 Earnings

Glaukos Corp (NYSE:GKOS) on Wednesday reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.

Benzinga • 9 hours ago

Glaukos Sets $1 Billion 2027 Sales Goal: Rapid Earnings Reaction

Glaukos raised its 2026 sales forecast to $775 million to $785 million and set a preliminary 2027 target of $1 billion, after third-quarter sales jumped 58% to $211.0 million. Profit is thinner than the adjusted figures suggest.

The Motley Fool • 2 hours ago

Why Glaukos Shares Are Trading Higher By Over 17%; Here Are 20 Stocks Moving Premarket

Shares of Glaukos Corp (NYSE:GKOS) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.

Benzinga • 13 hours ago

Glaukos Q3 Earnings Call Highlights

Glaukos NYSE: GKOS reported record third-quarter consolidated net sales of $211 million, up 58% from the year-earlier period, led by growth in its Epioxa corneal health therapy and iDose TR glaucoma treatment. The company raised its full-year 2026 revenue outlook and introduced a preliminary target of $1 billion in revenue for 2027.

MarketBeat • a day ago

Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript

Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript

Seeking Alpha • 19 hours ago

Glaukos Announces Third Quarter 2026 Financial Results

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the third quarter ended September 30, 2026. Key highlights include: Record net sales of $211.0 million in Q3 2026 increased 58% year-over-year on a reported and constant currency basis. U.S. Glaucoma record net sales of $118.6 mil.

Business Wire • Oct 28, 2026

Glaukos (GKOS) Q3 Earnings and Revenues Surpass Estimates

Glaukos (GKOS) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to a loss of $0.16 per share a year ago.

Zacks Investment Research • 21 hours ago

Compared to Estimates, Glaukos (GKOS) Q3 Earnings: A Look at Key Metrics

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Investment Research • a day ago

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.

Zacks Investment Research • Oct 14, 2026

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy

Ophthalmic pharmaceutical and medical technology firm Glaukos Corporation (NYSE:GKOS) reported successful topline outcomes from its latest Phase 4 clinical study.

Benzinga • Oct 9, 2026